Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 13/20 | 0.45 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.41 |
| ▸ | AOC2 | O75106 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30181581 | 0.88 | OPRL1 (0.47) | OPRL1C5AR1OPRM1OPRK1AOC2 | |
| SCHEMBL23994024 | 0.88 | OPRL1 (0.47) | OPRL1C5AR1OPRM1OPRK1AOC2 | |
| SCHEMBL23994241 | 0.85 | OPRL1 (0.45) | OPRL1C5AR1OPRM1OPRK1AOC2 | |
| SCHEMBL30181942 | 0.84 | OPRL1 (0.44) | OPRL1C5AR1OPRM1OPRK1AOC2 | |
| SCHEMBL23993157 | 0.82 | OPRL1 (0.48) | OPRL1C5AR1OPRM1OPRK1ALDH1A1 | |
| SCHEMBL23991954 | 0.82 | OPRL1 (0.48) | OPRL1C5AR1OPRM1OPRK1ALDH1A1 | |
| SCHEMBL30181783 | 0.82 | OPRL1 (0.48) | OPRL1C5AR1OPRM1OPRK1ALDH1A1 | |
| SCHEMBL23994227 | 0.81 | DDR1 (0.35) | OPRL1OPRM1ALDH1A1 | |
| SCHEMBL30224278 | 0.81 | DDR1 (0.35) | OPRL1OPRM1ALDH1A1 | |
| SCHEMBL24204185 | 0.80 | OPRL1 (0.43) | OPRL1C5AR1OPRM1OPRK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12110294-B2 | CD73 compounds | GILEAD SCIENCES, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| US-20230039553-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | OPRL1 2154/4885C5AR1 1101/4885OPRM1 2621/4885 |
| US-12110294-B2 | CD73 compounds | ENTPD5, ENTPD1, NT5E | OPRL1 2020/4885C5AR1 896/4885OPRM1 2153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.